Hypofractionated radiotherapy for prostate cancer: how far can we go?

Aluwini, Shafak

The general purpose of this thesis was to investigate the feasibility of moderate and extreme hypofractionated radiotherapy for prostate cancer, with emphasis on treatment induced side effects. In this context, in all clinical studies toxicity was scored by both physicians and patients, using patient self-assessment questionnaires (PSAQ).

Additional Metadata
Promotor	B.J.M. Heijmen (Ben) , L. Incrocci (Luca)
Publisher	Erasmus University Rotterdam
ISBN	978-94-028-0352-5
Persistent URL	hdl.handle.net/1765/94037
Organisation	Department of Radiation Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Aluwini, S. (2016, November 16). Hypofractionated radiotherapy for prostate cancer: how far can we go?. Retrieved from http://hdl.handle.net/1765/94037

View at Worldcat

Free Full Text ( Final Version , 18mb )

Additional Files
stellingen-Aluwini.pdf Final Version , 142kb

See Also
article High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: A 7-year experience S. Aluwini (Shafak), P.H. van Rooij (Peter), W.J. Kirkels (Wim), P.P. Jansen (Peter), J. Praag (John), C.H. Bangma (Chris) and I.-K.K. Kolkman-Deurloo (Inger-Karina)
article CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: Early experience, feasibility, and tolerance S. Aluwini (Shafak), P.H. van Rooij (Peter), M.S. Hoogeman (Mischa), C.H. Bangma (Chris), W.J. Kirkels (Wim), L. Incrocci (Luca) and I.-K.K. Kolkman-Deurloo (Inger-Karina)
article Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer S. Aluwini (Shafak), W.M.H. Busser (Wendy M.H.), W.G. Alemayehu (Wendimagegn Ghidey), J.L. Boormans (Joost), W.J. Kirkels (Wim), P.P. Jansen (Peter), J. Praag (John), C.H. Bangma (Chris) and I.-K.K. Kolkman-Deurloo (Inger-Karina)
article Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial S. Aluwini (Shafak), F.J. Pos (Floris), E. Schimmel (Erik), E. van Lin (Emile), S. Krol (Stijn), P.-P. van der Toorn (Peter-Paul), H. de Jager (Hanja), M.L.P. Dirkx (Maarten), W.G. Alemayehu (Wendimagegn Ghidey), B.J.M. Heijmen (Ben), et al. L. Incrocci (Luca)
article Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial S. Aluwini (Shafak), F.J. Pos (Floris), E. Schimmel (Erik), S. Krol (Stijn), P.-P. van der Toorn (Peter-Paul), H. de Jager (Hanja), W.G. Alemayehu (Wendimagegn Ghidey), W.D. Heemsbergen (Wilma), B.J.M. Heijmen (Ben) and L. Incrocci (Luca)
article Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results S. Aluwini (Shafak), P.H. van Rooij (Peter), M.S. Hoogeman (Mischa), W.J. Kirkels (Wim), I.-K.K. Kolkman-Deurloo (Inger-Karina) and C.H. Bangma (Chris)
article HDR monotherapy for prostate cancer: A simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation I.-K.K. Kolkman-Deurloo (Inger-Karina), M.A. Roos (Martin) and S. Aluwini (Shafak)

Hypofractionated radiotherapy for prostate cancer: how far can we go?

Publication

Publication

article
High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: A 7-year experience

article
CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: Early experience, feasibility, and tolerance

article
Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

article
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial

article
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial

article
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results

article
HDR monotherapy for prostate cancer: A simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation

About

Hypofractionated radiotherapy for prostate cancer: how far can we go?

Publication

Publication

article High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: A 7-year experience

article CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: Early experience, feasibility, and tolerance

article Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

article Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial

article Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial

article Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results

article HDR monotherapy for prostate cancer: A simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation

Workflow

Workflow

Add Content

article
High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: A 7-year experience

article
CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: Early experience, feasibility, and tolerance

article
Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

article
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial

article
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial

article
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results

article
HDR monotherapy for prostate cancer: A simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation